132 related articles for article (PubMed ID: 35843802)
1. Impact of a pharmacist-led tacrolimus management protocol in the outpatient setting.
Owen K; Winters H; Palettas M; Witkowsky O
J Am Pharm Assoc (2003); 2022; 62(6):1912-1918. PubMed ID: 35843802
[TBL] [Abstract][Full Text] [Related]
2. Impact of a Clinical Solid Organ Transplant Pharmacist on Tacrolimus Nephrotoxicity, Therapeutic Drug Monitoring, and Institutional Revenue Generation in Adult Kidney Transplant Recipients.
Griffin SP; Nelson JE
Prog Transplant; 2016 Dec; 26(4):314-321. PubMed ID: 27628498
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a Standardized Tacrolimus Therapeutic Drug Monitoring Protocol in Stable Kidney Transplant Recipients.
Ky TQ; Silas NP; Taylor RM; Barakat AO; Harb R; Laviste NC; Park JM
Prog Transplant; 2022 Sep; 32(3):212-218. PubMed ID: 35695240
[No Abstract] [Full Text] [Related]
4. A pharmacist-led intervention to improve kidney transplant recipient outcomes and identify patients at risk of highly variable trough tacrolimus levels: a cohort study.
Lhermitte R; Le Daré B; Laval F; Lemaitre F; Troussier B; Morin MP; Vigneau C; Chemouny JM; Bacle A
Eur J Hosp Pharm; 2024 Jun; 31(4):314-320. PubMed ID: 36737230
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.
Solomon S; Colovai A; Del Rio M; Hayde N
Pediatr Nephrol; 2020 Feb; 35(2):261-270. PubMed ID: 31732803
[TBL] [Abstract][Full Text] [Related]
6. Impact of pharmacist-led post-transplant medication management for kidney transplant recipients: A retrospective pre- and post-intervention study.
Yang H; Li L; Hu X; Wang W; Yang X; Liu H; Ren L; Zhang X; Liu L
J Clin Pharm Ther; 2019 Aug; 44(4):603-610. PubMed ID: 30883843
[TBL] [Abstract][Full Text] [Related]
7. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.
Viesselmann CW; Descourouez JL; Jorgenson MR; Radke NA; Odorico JS
Pharmacotherapy; 2016 Mar; 36(3):335-41. PubMed ID: 26877191
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus time in therapeutic range and long-term outcomes in heart transplant recipients.
Adie SK; Bitar A; Konerman MC; Dorsch MP; Andrews CA; Pogue K; Park JM
Pharmacotherapy; 2022 Feb; 42(2):106-111. PubMed ID: 34882822
[TBL] [Abstract][Full Text] [Related]
9. Impact of the implementation of a pharmacist-driven immunosuppression drug monitoring protocol for hematopoietic stem cell transplant recipients.
Gawedzki P; Collins J
J Oncol Pharm Pract; 2021 Dec; 27(8):1907-1913. PubMed ID: 33250016
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implications of Tacrolimus Time in Therapeutic Range and Intrapatient Variability in Urban Renal Transplant Recipients Undergoing Early Corticosteroid Withdrawal.
Pierce DR; West-Thielke P; Hajjiri Z; Gaitonde S; Tzvetanov I; Benedetti E; Lichvar AB
Transplant Direct; 2021 Jun; 7(6):e698. PubMed ID: 34036168
[TBL] [Abstract][Full Text] [Related]
11. Pharmacist Impact on Tacrolimus Serum Concentrations in Liver Transplant Patients.
Schuh MJ; Massoglia G
Consult Pharm; 2018 May; 33(5):268-272. PubMed ID: 29789048
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Everolimus Plus Standard-Dose Tacrolimus Immunosuppression in De Novo Kidney Transplant: A Retrospective, Single-Center Study of 225 Transplants.
Okabe Y; Noguchi H; Sato Y; Mei T; Kaku K; Ueki K; Tsuchimoto A; Nakamura M
Exp Clin Transplant; 2022 Mar; 20(4):362-369. PubMed ID: 35475420
[TBL] [Abstract][Full Text] [Related]
13. Tacrolimus time-in-therapeutic range is associated with freedom from acute rejection and graft failure following intestinal transplantation.
Santeusanio AD; Gu A; Weinberg AD; Moon J; Iyer KR
Clin Transplant; 2021 Jun; 35(6):e14291. PubMed ID: 33740822
[TBL] [Abstract][Full Text] [Related]
14. Impact of a pharmacist-led, mHealth-based intervention on tacrolimus trough variability in kidney transplant recipients: A report from the TRANSAFE Rx randomized controlled trial.
Fleming JN; Gebregziabher M; Posadas A; Su Z; McGillicuddy JW; Taber DJ
Am J Health Syst Pharm; 2021 Jul; 78(14):1287-1293. PubMed ID: 33821958
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients.
Lichvar A; Tremblay S; Naik D; Lipscomb J; King E; Vinks AA; Christians U; Alloway RR
Pharmacotherapy; 2019 May; 39(5):564-575. PubMed ID: 30892704
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study.
Krisl A; Stampf S; Hauri D; Binet I; Mueller T; Sidler D; Hadaya K; Golshayan D; Pascual M; Koller M; Dickenmann M; The Swiss Transplant Cohort Study Stcs
Swiss Med Wkly; 2020 Nov; 150():w20354. PubMed ID: 33277913
[TBL] [Abstract][Full Text] [Related]
17. Impact of transplant pharmacists on length of stay and 30-day hospital readmission rate: a single-centre retrospective cohort study.
Alsheikh R; Johnson K; Dauenhauer A; Kadambi P
Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e146-e150. PubMed ID: 33380430
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus and tacrolimus coefficient of variation is associated with rejection, donor-specific antibodies, and nonadherence.
Pizzo HP; Ettenger RB; Gjertson DW; Reed EF; Zhang J; Gritsch HA; Tsai EW
Pediatr Nephrol; 2016 Dec; 31(12):2345-2352. PubMed ID: 27286686
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP3A5 phenotype on tacrolimus time in therapeutic range and clinical outcomes in pediatric renal and heart transplant recipients.
Leino AD; Park JM; Pasternak AL
Pharmacotherapy; 2021 Aug; 41(8):649-657. PubMed ID: 34129685
[TBL] [Abstract][Full Text] [Related]
20. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
